Amr Mohamed, Brandon Twardy, Magdi A Zordok, Khuram Ashraf, Ayman Alkhoder, Kelly Schrapp, Conor Steuer, Zhengjia Chen, Suchita Pakkala, Rathi Pillai, J Trad Wadsworth, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Taofeek K Owonikoko, Fadlo R Khuri, Dong M Shin, Madhusmita Behera, Nabil F Saba
BACKGROUND: Cisplatin-based chemoradiotherapy is standard of care for locally advanced squamous cell carcinoma of the head and neck. This systemic review compared efficacy and safety of weekly vs triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck. METHODS: Among 1500 prospective studies published from 1970 to 2015, 39 (18 weekly, 21 triweekly) including 3668 patients qualified for inclusion. Clinical outcomes were analyzed using weighted estimates and 2-tailed t test for comparisons; significance level was 0...
May 2019: Head & Neck